Design and Rationale of the GAUSS-2 Study Trial: A Double-Blind, Ezetimibe-Controlled Phase 3 Study of the Efficacy and Tolerability of Evolocumab (AMG 145) in Subjects With Hypercholesterolemia Who Are Intolerant of Statin Therapy

Discontinuation of Statins in Routine Care Settings

(2013) Huabing Zhang et al.   ANNALS OF INTERNAL MEDICINE

Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism

(2013) Ernst J. Schaefer   CURRENT OPINION IN LIPIDOLOGY

Efficacy and Safety of AMG 145, a Fully Human Monoclonal Antibody to PCSK9: Data from Four Phase 2 Studies in Over 1200 Patients

(2013) Frederick Raal et al.   Journal of Clinical Lipidology

Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia

(2012) Frederick Raal et al.   CIRCULATION

Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial

(2012) Maartje E. Visser et al.   EUROPEAN HEART JOURNAL

Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients

(2012) David Sullivan et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels

(2012) Clapton S. Dias et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy

(2012) James M. McKenney et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study

(2012) Michael J Koren et al.   LANCET

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study

(2012) Robert P Giugliano et al.   LANCET

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

(2012) Marina Cuchel et al.   LANCET

Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol

(2012) Evan A. Stein et al.   NEW ENGLAND JOURNAL OF MEDICINE

Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia

(2012) Eli M. Roth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Proceedings of a Canadian Working Group Consensus Conference

(2011) G.B. John Mancini et al.   CANADIAN JOURNAL OF CARDIOLOGY

Statin Discontinuation in High-Risk Patients: A Systematic Review of the Evidence

(2011) Yessica-Haydee Gomez Sandoval et al.   CURRENT PHARMACEUTICAL DESIGN

Needed: Pragmatic Clinical Trials for Statin-Intolerant Patients

(2011) Patricia Maningat et al.   NEW ENGLAND JOURNAL OF MEDICINE

Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy

(2010) Andrew L. Mammen et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

The SLCO1B1*5Genetic Variant Is Associated With Statin-Induced Side Effects

(2009) Deepak Voora et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates

(2009) J. C. Y. Chan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study

(2008)   NEW ENGLAND JOURNAL OF MEDICINE